Process of vaccination to seep up in India by next January
Centre prepares production procedure and makes 28 crore doses of Covid vaccines available for the future
India will get vaccines of 28 crore doses this month, which will be including 22 crores of Covishield, manufactured by the Serum Institute of India and 6 crore doses of Covaxin.
The stock will also include 60 lakh Zydus Cadila's ZyCoV-D doses, reports say.
An idea has been made which opens that India will have a capacity of more than 30 crores by next year per month, which will include Covishield, Covaxin, ZyCoV-D and Biological E.
The famous company Zydus Cadila's ZyCoV-D are already ready with 60 lakh doses and the Biological E will be submitting the data till November end of phase -3 trials.
The Biological E is the third Indian company to make Covid-19 vaccines.
The company has also started stockpile doses.
Biological E will be providing 30 crore doses and another company that is expected to provide doses is Genova which is the fourth Indian company doing trials of mRNA vaccines.
The famous company Zydus Cadila's ZyCoV-D are already ready with 60 lakh doses and the Biological E will be submitting the data till November end of phase -3 trials.India is expected to get Gennova's mRNA vaccine doses by February.
On September 2, NITI Aayog Member (Health) VK Paul had said that the Hyderabad-based pharmaceutical company, Biological E, is all set to launch its Covid vaccine by October 2021.
Paul said that Phase 3 of Biological E's trial is underway. India procured more than 26 crore doses in the month of September also.
The Centre had plans to achieve 100 crore doses by the upcoming week.
It was expected to reach the assumed target between October 10 to October 12.
There has been a delay and decline in Covid vaccination due to the festival season and hesitation for the second dose.
India may accelerate the export of Covid-19 vaccines under its humanitarian initiative 'Vaccine Maitri' by December after having an excess number of doses in the country.
Be the first to start a discussion here. Sign-in to write a comment now!